HomepageNCYT • LON
Novacyt
GBX 51,80
29 jan, 17:30:00 UTC · GBX · LON · Disclaimer
AandeelEffect wordt verhandeld in GB
Vorige slotkoers
GBX 51,80
Dag-range
GBX 51,60 - GBX 52,80
Jaar-range
GBX 42,95 - GBX 137,00
Beurswaarde
43,51 mln. EUR
Gem. volume
220,40K
Koers/winst
-
Dividendrendement
-
Primaire beurs
EPA
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(GBP)jun 2024Wijziging j-o-j
Opbrengst
5,16 mln.209,13%
Bedrijfskosten
7,92 mln.92,89%
Netto inkomsten
-8,85 mln.-112,01%
Netto winstmarge
-171,4731,41%
Winst per aandeel
EBITDA
-12,02 mln.-324,07%
Effectief belastingtarief
1,22%
Totale activa
Totale passiva
(GBP)jun 2024Wijziging j-o-j
Contanten en kortetermijnbeleggingen
32,95 mln.-59,69%
Totale activa
99,40 mln.-24,78%
Totale passiva
28,99 mln.16,70%
Totaal aandelenvermogen
70,41 mln.
Uitstaande aandelen
70,63 mln.
Koers-boekwaardeverhouding
0,52
Rendement op activa
-36,30%
Rendement op kapitaal
-43,18%
Nettomutatie in liquide middelen
(GBP)jun 2024Wijziging j-o-j
Netto inkomsten
-8,85 mln.-112,01%
Operationele kasstroom
-4,54 mln.-59,67%
Kasstroom uit beleggingen
-566,50K-212,18%
Kasstroom uit financiering
-430,50K-61,24%
Nettomutatie in liquide middelen
-5,56 mln.-112,16%
Vrije kasstroom
-17,73 mln.-943,16%
Over
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Opgericht
2006
Werknemers
240
Zoeken
Zoekopdracht wissen
Zoekfunctie sluiten
Google-apps
Hoofdmenu